Dr. Reddy’s

Investor Presentation - 2016 Dr. Reddy’s Laboratories Ltd. 6 Executive Summary • During the last decade, our top line grew at 18% CAGR with healthy profitability, on the back of strong performance from US generics and branded formulations in Emerging markets.

  2016, Reddy s, Reddy, 2016 dr